Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2a Study of TPN-101 in Patients With Progressive Supranuclear Palsy (PSP)

NCT04993768 is registered in ClinicalTrials.gov with Transposon Therapeutics, Inc. as lead sponsor.

NCT NCT04993768
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04993768 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2a Study of TPN-101 in Patients With Progressive Supranuclear Palsy (PSP)
Lead sponsor
Transposon Therapeutics, Inc.
Phase
Phase 2
Overall status
Completed
Start date
December 12, 2021
Completion date
March 24, 2024
Enrollment
42 (actual)
Sites
14

Conditions

As the registry lists them; a condition with its own page is linked.

progressive supranuclear palsy